Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Heparin Mimetics: Their Therapeutic Potential.

Mohamed S, Coombe DR.

Pharmaceuticals (Basel). 2017 Oct 2;10(4). pii: E78. doi: 10.3390/ph10040078. Review.

2.

Identification of Heparin Modifications and Polysaccharide Inhibitors of Plasmodium falciparum Merozoite Invasion That Have Potential for Novel Drug Development.

Boyle MJ, Skidmore M, Dickerman B, Cooper L, Devlin A, Yates E, Horrocks P, Freeman C, Chai W, Beeson JG.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00709-17. doi: 10.1128/AAC.00709-17. Print 2017 Nov.

PMID:
28893781
3.

Assessment of Heparanase-Mediated Angiogenesis Using Microvascular Endothelial Cells: Identification of λ-Carrageenan Derivative as a Potent Anti Angiogenic Agent.

Poupard N, Badarou P, Fasani F, Groult H, Bridiau N, Sannier F, Bordenave-Juchereau S, Kieda C, Piot JM, Grillon C, Fruitier-Arnaudin I, Maugard T.

Mar Drugs. 2017 May 9;15(5). pii: E134. doi: 10.3390/md15050134.

4.

Glycosaminoglycans detection methods: Applications of mass spectrometry.

Kubaski F, Osago H, Mason RW, Yamaguchi S, Kobayashi H, Tsuchiya M, Orii T, Tomatsu S.

Mol Genet Metab. 2017 Jan - Feb;120(1-2):67-77. doi: 10.1016/j.ymgme.2016.09.005. Epub 2016 Sep 28. Review.

5.

The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.

Ribatti D.

Pharmaceuticals (Basel). 2010 Mar 8;3(3):482-513. Review.

6.

Susceptibility of enoxaparin reducing end amino sugars to periodate oxidation.

Alekseeva A, Elli S, Cosentino C, Torri G, Naggi A.

Carbohydr Res. 2014 Dec 5;400:33-43. doi: 10.1016/j.carres.2014.08.016. Epub 2014 Sep 10.

7.

Sulfated glycosaminoglycans control the extracellular trafficking and the activity of the metalloprotease inhibitor TIMP-3.

Troeberg L, Lazenbatt C, Anower-E-Khuda MF, Freeman C, Federov O, Habuchi H, Habuchi O, Kimata K, Nagase H.

Chem Biol. 2014 Oct 23;21(10):1300-1309. doi: 10.1016/j.chembiol.2014.07.014. Epub 2014 Aug 28.

8.

Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.

Alekseeva A, Casu B, Cassinelli G, Guerrini M, Torri G, Naggi A.

Anal Bioanal Chem. 2014 Jan;406(1):249-65. doi: 10.1007/s00216-013-7446-4. Epub 2013 Nov 20.

9.

Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

Alekseeva A, Casu B, Torri G, Pierro S, Naggi A.

Anal Biochem. 2013 Mar 1;434(1):112-22. doi: 10.1016/j.ab.2012.11.011. Epub 2012 Nov 29.

10.

Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.

Rusnati M, Bugatti A, Mitola S, Leali D, Bergese P, Depero LE, Presta M.

Sensors (Basel). 2009;9(8):6471-503. doi: 10.3390/s90806471. Epub 2009 Aug 20.

11.

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y.

Clin Cancer Res. 2011 Mar 15;17(6):1382-93. doi: 10.1158/1078-0432.CCR-10-2476. Epub 2011 Jan 21.

12.

Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Bitan M, Weiss L, Zeira M, Zcharia E, Slavin S, Nagler A, Vlodavsky I.

PLoS One. 2010 Apr 15;5(4):e10135. doi: 10.1371/journal.pone.0010135.

13.

Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.

Casu B, Naggi A, Torri G.

Matrix Biol. 2010 Jul;29(6):442-52. doi: 10.1016/j.matbio.2010.04.003. Epub 2010 Apr 21. Review.

14.

Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

Bitan M, Weiss L, Reibstein I, Zeira M, Fellig Y, Slavin S, Zcharia E, Nagler A, Vlodavsky I.

Mol Immunol. 2010 Jun;47(10):1890-8. doi: 10.1016/j.molimm.2010.03.014.

15.

Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.

Garg HG, Mrabat H, Yu L, Freeman C, Li B, Zhang F, Linhardt RJ, Hales CA.

Carbohydr Res. 2008 Sep 22;343(14):2406-10. doi: 10.1016/j.carres.2008.06.022. Epub 2008 Jul 4.

16.

The chemical neurobiology of carbohydrates.

Murrey HE, Hsieh-Wilson LC.

Chem Rev. 2008 May;108(5):1708-31. doi: 10.1021/cr078215f. Epub 2008 May 2. Review. No abstract available.

17.

Heparanase: a target for drug discovery in cancer and inflammation.

McKenzie EA.

Br J Pharmacol. 2007 May;151(1):1-14. Epub 2007 Mar 5. Review.

18.

Structural specificity of heparin binding in the fibroblast growth factor family of proteins.

Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2357-62. Epub 2003 Feb 25.

Supplemental Content

Support Center